{"filing":{"accession_number":"0001628280-26-058519","cik":"0000933974","ticker":"AZTA","company_name":"Azenta, Inc.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-22","primary_document":"azta-20260822.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/933974/000162828026058519/azta-20260822.htm"},"events":[{"id":29064,"run_id":26593,"accession_number":"0001628280-26-058519","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Dr. Martin D. Madaus was appointed as Interim President and CEO on August 22, 2026, following the resignation of John P. Marotta. Madaus brings significant industry experience as a former CEO of Millipore, Ortho Clinical Diagnostics, and Roche Diagnostics North America.","company_name":"Azenta, Inc.","ticker":"AZTA","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31212,"accession_number":"0001628280-26-058519","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the resignation of President and CEO John P. Marotta and the appointment of Dr. Martin D. Madaus as Interim President and CEO on August 22, 2026. While both events occurred, the principal disclosed action centers on the appointment of an interim executive leader with significant industry experience (former CEO of Millipore, Ortho Clinical Diagnostics, and Roche Diagnostics North America) to lead the company during a transition period. The appointment of a new interim CEO is material to investors assessing leadership continuity and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:05:02.199194+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31213,"accession_number":"0001628280-26-058519","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing announces Dr. Martin Madaus's appointment as interim President and CEO, the principal disclosed action. While John Marotta's resignation is also mentioned, the press release centers on the leadership transition with Madaus taking the helm. The appointment of a new CEO is material to investors as it signals a change in company direction and leadership continuity during a transition period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:05:02.199194+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31212,"accession_number":"0001628280-26-058519","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the resignation of President and CEO John P. Marotta and the appointment of Dr. Martin D. Madaus as Interim President and CEO on August 22, 2026. While both events occurred, the principal disclosed action centers on the appointment of an interim executive leader with significant industry experience (former CEO of Millipore, Ortho Clinical Diagnostics, and Roche Diagnostics North America) to lead the company during a transition period. The appointment of a new interim CEO is material to investors assessing leadership continuity and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:05:02.199194+00:00","company_name":"Azenta, Inc.","ticker":"AZTA","filing_date":"2026-08-24"},{"id":31213,"accession_number":"0001628280-26-058519","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing announces Dr. Martin Madaus's appointment as interim President and CEO, the principal disclosed action. While John Marotta's resignation is also mentioned, the press release centers on the leadership transition with Madaus taking the helm. The appointment of a new CEO is material to investors as it signals a change in company direction and leadership continuity during a transition period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:05:02.199194+00:00","company_name":"Azenta, Inc.","ticker":"AZTA","filing_date":"2026-08-24"}]}